The impact of different durations of insulin treatment [insulin neutral protamine lispro/insulin lispro] on beta islet-cell function in newly diagnosed type 2 Diabetes after short-term intensive insulin therapy.

Trial Profile

The impact of different durations of insulin treatment [insulin neutral protamine lispro/insulin lispro] on beta islet-cell function in newly diagnosed type 2 Diabetes after short-term intensive insulin therapy.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2011

At a glance

  • Drugs Insulin neutral protamine lispro/insulin lispro (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 19 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top